AA
RYTM icon

ALPS Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

ALPS Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,000
Closed -$3.33M – 1078
2025
Q3 		$3.33M Sell
33,000
-1,178
-3% -$109K 0.02% 305
2025
Q2 		$2.16M Sell
34,178
-12,029
-26% -$737K 0.01% 357
2025
Q1 		$2.45M Sell
46,207
-3,493
-7% -$194K 0.01% 318
2024
Q4 		$2.78M Buy
+49,700
New +$2.75M 0.02% 300
2024
Q2 		– Sell
-42,419
Closed -$1.84M – 995
2024
Q1 		$1.84M Buy
42,419
+2,204
+5% +$96.5K 0.01% 368
2023
Q4 		$1.85M Sell
40,215
-1,736
-4% -$54.8K 0.01% 343
2023
Q3 		$962K Buy
41,951
+158
+0.4% +$3.54K 0.01% 464
2023
Q2 		$689K Buy
41,793
+4,405
+12% +$79.5K 0.01% 557
2023
Q1 		$667K Sell
37,388
-810
-2% -$20.3K 0.01% 537
2022
Q4 		$1.11M Buy
+38,198
New +$982K 0.01% 442
2019
Q4 		– Sell
-68,850
Closed -$1.49M – 855
2019
Q3 		$1.49M Sell
68,850
-3,220
-4% -$69.1K 0.01% 247
2019
Q2 		$1.59M Sell
72,070
-11,045
-13% -$279K 0.01% 258
2019
Q1 		$2.28M Buy
83,115
+3,594
+5% +$103K 0.02% 211
2018
Q4 		$2.14M Buy
79,521
+19,045
+31% +$526K 0.02% 213
2018
Q3 		$1.76M Buy
60,476
+20,524
+51% +$649K 0.01% 268
2018
Q2 		$1.25M Buy
39,952
+3,359
+9% +$91.8K 0.01% 295
2018
Q1 		$728K Buy
+36,593
New +$972K 0.01% 371

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ALPS Advisors's RYTM Position: Q4 2025 in Review

ALPS Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 33,000 shares — an estimated $3.33M sold.

ALPS Advisors first reported a position in RYTM in Q1 2018 and held it in 17 quarters. The position peaked at $3.33M in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • ALPS Advisors reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 33,000 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $3.33M.
  • ALPS Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2018 and held it in 17 quarters.
  • ALPS Advisors's Rhythm Pharmaceuticals position peaked at $3.33M in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.